Lifecore Biomedical, Inc. engages in the development and manufacturing of pharmaceuticals products and services. It focuses on selling products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans, and non-HA products for medical use primarily in the Ophthalmic, Orthopedic and other markets. The company was founded by Otto Sartorius in 1965 and is headquartered in Chaska, MN.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Lifecore Biomedical signed a new agreement to transfer a commercially marketed injectable drug product to its pipeline, supporting technical transfer and commercial manufacturing. - The agreement with a global pharmaceutical company marks Lifecore's seventh late-stage commercial program and eleventh program added to its pipeline in 2026. - The program is expected to generate commercial revenues in 2028 and is positioned to become one of Lifecore's largest contracts. - Lifecore's late-stage pipeline now contains thirteen programs with potential to generate commercial revenues by the end of 2028.
- Lifecore Biomedical signed two new CDMO manufacturing agreements with an existing U.S. biopharmaceutical customer, including a commercial site transfer for a currently marketed product. - The site transfer agreement marks Lifecore's fourth such win in five months, reflecting the company's successful commercial strategy prioritizing higher-probability late-stage programs. - A second agreement expands manufacturing of an ophthalmic disease treatment to a new delivery system, with production shifting from Europe to Lifecore. - Both programs are expected to contribute to Lifecore's 2028 commercial revenue, strengthening the company's growing late-stage pipeline.
- Lifecore Biomedical has signed a second development services agreement with Indomo to manufacture clinical batches of DT-001, a corticosteroid drug candidate for inflammatory acne treatment. - Indomo's investigational ClearPen system combines triamcinolone acetonide with a proprietary self-injection device and microneedle for at-home administration. - The partnership aims to prepare DT-001 for Phase 2 clinical trials in 2026, addressing a significant access gap where only one million of 50 million Americans with acne receive corticosteroid injections. - The collaboration highlights Lifecore's expansion beyond ophthalmic therapies into autoinjector technologies and Indomo's mission to bring medical-grade dermatological care to patients' homes.
